Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ALKS 2680

Next Previous
X
Search
Drug Profile

ALKS 2680

Alternative Names: ALKS-2680

Latest Information Update: 27 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alkermes
  • Class Sleep disorder therapies
  • Mechanism of Action Orexin receptor type 2 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Narcolepsy
  • Phase I Idiopathic hypersomnia

Most Recent Events

  • 26 Jul 2024 Alkermes initates the phase II Vibrance 2 trial in Narcolepsy in USA (PO) (NCT06555783)
  • 03 Jun 2024 Efficacy and adverse event data from a phase Ib trial in Narcolepsy released by Alkermes
  • 01 May 2024 Alkermes plans a phase II trial in Narcolepsy type 2 in the second half of 2024

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top